Value of precardioversion transesophageal echocardiography in managing cardioversion in atrial fibrillation: Reply  by Seidl, Karlheinz
LETTERS TO THE EDITOR
Value of Precardioversion Transesophageal
Echocardiography in Managing Cardioversion
of Atrial Fibrillation
We read with great interest the report of Seidl et al. (1) regarding
the value of pre-cardioversion transesophageal echocardiography
(TEE) in the management of cardioversion of atrial fibrillation
among patients who had already received conventional therapy of
three weeks of therapeutic (INR 2) warfarin. Though a similarly
low (0.8%) clinical thromboembolism rate was reported among
those who underwent TEE prior to cardioversion and those who
did not undergo TEE before cardioversion, we respectfully dis-
agree with the researchers’ conclusion that “the use of TEE-guided
electrical cardioversion does not reduce the [clinical] embolic risk.”
Such a conclusion can only be supported by studies in which all
patients undergo cardioversion irrespective of the TEE data.
Although the overall clinical thromboembolism rate was similar
among both groups in the Seidl et al. study, high-risk patients—
those with TEE evidence of left atrial thrombi and those with
moderate or severe spontaneous echocardiographic contrast—did not
undergo cardioversion. This very likely reduced the overall thrombo-
embolism rate among the TEE group. Furthermore, the frequency of
recognized clinical risk factors for stroke, including prior transient
ischemic event/stroke and depressed left ventricular ejection fraction,
proved significantly higher in the TEE group. This may partially
explain the relatively high frequency of left atrial thrombi and dense
spontaneous echocardiographic contrast in the TEE group.
We believe that clinical thromboembolism after direct current
(DC) cardioversion is related both to migration of thrombi present at
the time of cardioversion and to the formation (and migration) of
thrombi in the post-cardioversion period (2). Data from our group (3)
and the Assessment of Cardioversion Using Transesophageal Echo-
cardiography (ACUTE) trial (4) support equivalence for conventional
therapy and TEE-guided early cardioversion approaches. Though we
had previously considered the combination of three weeks of warfarin
followed by TEE to be unnecessary and relatively cost-ineffective (5)
we interpret the data by Seidl et al. as suggesting that such an
approach should now be more fully explored.
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REPLY
This is in reply to the communication by Manning and colleagues
regarding our manuscript “Embolic Events in Patients With Atrial
fibrillation: Value of Transesopageal Echocardiography to Guide
DC-Cardioversion” (1).
In accordance with you, we believe that clinical thromboembo-
lism after direct current (DC) cardioversion is related both to
migration of thrombi present at the time of cardioversion and to
the formation and migration of thrombi in the postcardioversion
period.
Our study was a prospective single-center observational study
designed on an intention-to-cardiovert basis. During the first
two years, patients were treated according to recommendations
of the American College of Chest Physicians. In these patients
no transesophageal echocardiography (TEE) was performed.
In our opinion we would have detected a similar proportion of
left atrial thrombl in these patients. In patients in whom a TEE
was performed, all patients with evidence of thrombi were not
cardioverted. Patients in the TEE group were older and more
often had organic heart disease, impaired left ventricular function,
episodes of atrial fibrillation lasting longer than 48 h, and a larger
left atrium. However, all these differences were minor and, in our
opinion, not clinically relevant. A similar prevalence of thrombi
like in the TEE-guided group should be expected in the conven-
tional treatment group. These patients were not excluded from
cardioversion, because they were not identified. Nevertheless, the
embolic rate was similar.
One might argue that, in our study group (1), patients in the
conventional group differed from those in the TEE-guided group.
However, when comparing the patient group in the conventional
arms of the ACUTE study (2) with our patients in the TEE-
guided group, no major difference was observed. This supports the
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hypothesis that the prevalence of thrombi is about 7% in patients
after at least three weeks of effective anticoagulation.
Because this was a single-center observational study, I clearly
state that randomized studies evaluating this issue are needed.
With knowledge of this in mind, we did not conclude that
TEE-guided electrical cardioversion does not reduce the em-
bolic risk; rather, we conclude that our study may have two
clinical implications. First, TEE before DC cardioversion is not
needed in patients with effective anticoagulation at least three
weeks before cardioversion, and, second, if TEE is performed
early, more thrombi will be detected and more patients will be
excluded from cardioversion. However, in patients with a
normal TEE study, early cardioversion can be performed safely.
The impact of thrombi detected during TEE on long-term
outcome must be evaluated.
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